Breast Cancer Version 3.2014 Clinical Practice Guidelines in Oncology
Breast Cancer Version 3.2014 Clinical Practice Guidelines in Oncology
复制标题
DOI：
10.6004/jnccn.2014.0058
复制
发表时间：
2014-04-01
影响因子：
13.4
通讯作者：
Kumar, Rashmi
中科院分区：
文献类型：
--
作者：
Gradishar, William J.;Anderson, Benjamin O.;Kumar, Rashmi
乳腺癌是美国女性最常见的恶性肿瘤，是仅次于肺癌的癌症死亡原因。乳腺癌的整体治疗包括通过手术、放射治疗或两者联合治疗局部疾病，以及通过细胞毒性化疗、内分泌治疗、生物治疗或这些治疗的组合治疗全身疾病。本文讨论了针对大型临床 II 期和 III 期肿瘤管理的 NCCN 指南。这些指南是 NCCN 乳腺癌专家组成员的工作成果。需要专家的医学临床判断才能将这些指南应用于个体患者，以提供最佳的护理。尽管指南中的每个决策点均未注明，但患者参与前瞻性临床试验是所有阶段乳腺癌治疗的首选选择。
Breast cancer is the most common malignancy in women in the United States and is second only to lung cancer as a cause of cancer death. The overall management of breast cancer includes the treatment of local disease with surgery, radiation therapy, or both, and the treatment of systemic disease with cytotoxic chemotherapy, endocrine therapy, biologic therapy, or combinations of these. The NCCN Guidelines specific to management of large clinical stage II and III tumors are discussed in this article. These guidelines are the work of the members of the NCCN Breast Cancer Panel. Expert medical clinical judgment is required to apply these guidelines in the context of an individual patient to provide optimal care. Although not stated at every decision point of the guidelines, patient participation in prospective clinical trials is the preferred option of treatment for all stages of breast cancer.